ACAD

Acadia Pharmaceuticals Inc

20.44

Oct 20 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: AXSM HRMY NBIX ALKS TSHA JAZZ SUPN XENE NGNE BIIB

| Held by: IJR VTI IWM VB XBI VBK VXF IBB IJT IWO

Index	RUT
Market Cap	3.52B
Enterprise Value	2.64B
Income	380.48M
Sales	1.14B
Book/sh	7.59
Cash/sh	5.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	798
IPO	May 27, 2004

P/E	9.21
Forward P/E	21.79
PEG	-
P/S	3.09
P/B	2.69
P/C	3.68
P/FCF	24.19
EV/EBITDA	26.82
EV/Sales	2.32
Quick Ratio	3.30
Current Ratio	3.39
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	2.22
EPS next Y	0.94
EPS next Q	0.20
EPS this Y	-72.90%
EPS next Y	50.50%
EPS next 5Y	-12.30%
EPS past 3/5Y	- -
Sales past 3/5Y	27.48% 19.39%
EPS Y/Y TTM	68.42%
Sales Y/Y TTM	11.75%
EPS Q/Q	15.24%
Sales Q/Q	16.40%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	163.93% 3.85%

Insider Own	1.31%
Insider Trans	-2.04%
Inst Own	98.21%
Inst Trans	1.41%
ROA	25.64%
ROE	35.74%
ROIC	27.85%
Gross Margin	91.13%
Oper. Margin	7.59%
Profit Margin	33.42%
SMA20	1.13%
SMA50	-18.83%
SMA200	-14.63%
Trades

Shs Outstand	172.13M
Shs Float	170.04M
Short Float	4.87%
Short Ratio	4.46
Short Interest	8.28M
52W High	30.96 -33.98%
52W Low	18.39 11.15%
Volatility	3.82% 3.94%
ATR (14)	0.80
RSI (14)	40.33
Beta	0.88
Rel Volume	0.00
Avg Volume	1.85M
Volume	0

Perf Week	9.77%
Perf Month	-22.56%
Perf Quarter	-18.11%
Perf Half Y	-6.24%
Perf YTD	-23.47%
Perf Year	-2.39%
Perf 3Y	-7.76%
Perf 5Y	13.68%
Perf 10Y	-14.66%
Recom	1.71
Target Price	30.53
Prev Close	20.44
Price	20.44
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-26	Downgrade	UBS	Buy → Neutral	$23
Mar-25-26	Upgrade	BofA Securities	Neutral → Buy	$29
Feb-24-26	Initiated	Wolfe Research	Outperform	$33
Feb-23-26	Upgrade	Mizuho	Neutral → Outperform	$35
Oct-21-25	Initiated	Citigroup	Buy	$33
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35

Show Previous Ratings

Sep-28-26 04:05PM	Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 (Business Wire)
11:30AM	3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI (Schaeffer's Research)
Sep-25-26 11:22AM	ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets (Stocktwits) -6.76%
11:01AM	Acadia chugs on with Alzheimers psychosis programme despite Phase II miss (Clinical Trials Arena)
09:21AM	Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimers data (BioPharma Dive)
06:41PM	Loading…
Sep-24-26 06:41PM	Acadia Pharmaceuticals Fell 19% Today. Heres Where the Stock Could Go in 2026 (TIKR) -12.78%
05:51PM	ACAD Stock Clocks Worst Day In 2 Years After Alzheimers Psychosis Drug Misses Main Goal Citi Cuts Drugs Success Odds To 20% (Stocktwits)
11:25AM	Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data (Proactive)
09:56AM	Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint (InvestorsHub)
07:00AM	Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP) (Business Wire)
Aug-28-26 09:15AM	Earnings To Watch: AcadeMedia AB (OSTO:ACAD) Q4 2026 -- GF Value Sees 6% Downside (GuruFocus.com)
Aug-24-26 03:01AM	European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union (Business Wire)
Aug-10-26 04:36PM	Immunic appoints Elena Ridloff to board of directors (Proactive)
Aug-05-26 01:06AM	ACADIA Pharmaceuticals Inc (ACAD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +6.08%
Aug-04-26 04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results (Business Wire) +6.01%
05:57PM	Loading…
Jul-30-26 05:57PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Jul-20-26 09:05AM	Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis (Business Wire)
Jul-15-26 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 (Business Wire)
Jul-06-26 09:04AM	Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer (Business Wire)
Jun-26-26 12:30PM	ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe (Stocktwits) +6.75%
06:49AM	DAYBU (trofinetide) Recommended for Approval in the European Union by CHMP (Business Wire)
05:24AM	On second try, Acadia drug gets nod from European regulators (BioPharma Dive)
Jun-12-26 05:31AM	Rapport fully prepared to launch seizure drug solo, CEO says (BioPharma Dive)
May-08-26 09:15AM	Earnings To Watch: AcadeMedia AB (OSTO:ACAD) Reports Q3 2026 Result (GuruFocus.com)
May-06-26 04:21PM	Acadia: Q1 Earnings Snapshot (Associated Press) +5.03%
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance (Business Wire)
Apr-30-26 04:05PM	Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career (Business Wire)
Apr-28-26 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Apr-17-26 09:05AM	Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-15-26 04:05PM	Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
09:05AM	Loading…
Apr-07-26 09:05AM	Acadia Pharmaceuticals Announces DAYBUE STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome (Business Wire)
Mar-25-26 02:51PM	Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback (Proactive) +5.01%
09:48AM	Arm upgraded, Mondelez downgraded: Wall Street's top analyst calls (The Fly)
Mar-12-26 04:05PM	Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-09-26 11:40AM	JAZZ or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Mar-05-26 05:07AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) (Zacks)
Mar-04-26 08:03AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Zacks)
Mar-03-26 04:05PM	Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors (Business Wire)
Mar-02-26 05:32PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 (MarketBeat) -7.13%
04:05PM	Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
01:45PM	Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains (Insider Monkey)
Feb-26-26 09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
08:30AM	ACADIA Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
12:05AM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-25-26 07:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates (Zacks)
06:32PM	ACADIA Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:37PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview (Business Wire)
Feb-23-26 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Feb-20-26 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-18-26 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
12:50AM	Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. (ACAD) For 2026 (Insider Monkey)
Feb-04-26 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
Feb-03-26 12:44PM	EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug (Benzinga) -5.24%
10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
Feb-02-26 04:05PM	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union (Business Wire)
12:10PM	Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-13-26 02:06PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf (MarketBeat)
09:00AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-12-26 04:01PM	Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience (Bloomberg)
11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Dec-22-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Dec-18-25 04:05PM	Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (Business Wire)
Dec-12-25 08:00AM	Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
Dec-03-25 09:17AM	Acadia to pivot to Alzheimers psychosis pipeline, accd to Wall Street analysts (Investing.com)
Nov-28-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-20-25 04:05PM	Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (Business Wire)
Nov-12-25 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
12:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:18PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview (Business Wire)
12:04PM	Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y (Zacks)
Oct-29-25 10:00AM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
12:00PM	Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:55AM	Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-22-25 03:41PM	Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-15-25 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +6.78% -5.15%
Oct-09-25 11:40AM	QGEN vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 09:04AM	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders (Business Wire)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) -9.92%
09:32AM	Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges (Investor's Business Daily)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 06 '26	Option Exercise	17.84	14,292	254,969	82,120	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 05 '26	Option Exercise	17.84	5,849	104,346	73,677	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 06 '26	Sale	29.22	14,292	417,604	67,828	Aug 07 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 05 '26	Sale	29.00	5,849	169,638	67,828	Aug 07 06:00 PM
Schneyer Mark C.	Officer	Aug 05 '26	Proposed Sale	27.15	5,849	158,800		Aug 05 04:49 PM
Thompson Elizabeth H.Z.	EVP, Head of Research & Dev	Jul 30 '26	Sale	26.13	16,558	432,663	18,994	Jul 31 06:00 PM
Kihara James	Officer	Jun 26 '26	Proposed Sale	26.00	11,421	297,000		Jun 26 03:09 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 26 '26	Sale	21.18	5,401	114,393	24,509	May 27 06:00 PM
JAMES K KIHARA	Officer	May 26 '26	Proposed Sale	21.18	5,401	114,394		May 26 04:02 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 04 '26	Sale	21.79	1,332	29,024	29,129	May 05 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 04 '26	Sale	21.79	3,506	76,396	66,145	May 05 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 07 '26	Sale	22.20	2,709	60,140	62,836	Apr 07 07:57 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 07 '26	Sale	22.20	1,030	22,866	27,865	Apr 07 07:55 PM
Owen Adams Catherine	Chief Executive Officer	Mar 24 '26	Option Exercise	0.00	23,509	0	26,444	Mar 26 08:00 PM
Owen Adams Catherine	Chief Executive Officer	Mar 25 '26	Sale	21.47	11,641	249,932	14,803	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Mar 24 '26	Option Exercise	0.00	7,515	0	15,124	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Mar 25 '26	Sale	21.47	3,844	82,531	11,280	Mar 26 08:00 PM
Thompson Elizabeth H.Z.	EVP, Head of Research & Dev	Mar 25 '26	Sale	21.47	3,435	73,749	3,280	Mar 26 08:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '26	Sale	21.65	1,109	24,011	26,885	Mar 26 08:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 25 '26	Sale	21.47	833	17,885	25,852	Mar 26 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 25 '26	Sale	21.47	4,177	89,680	57,299	Mar 26 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '26	Sale	21.65	3,208	69,456	60,269	Mar 26 08:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 06 '26	Option Exercise	0.00	12,944	0	14,559	Feb 10 06:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 09 '26	Sale	23.38	6,950	162,491	7,609	Feb 10 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 18 '25	Sale	23.69	10,262	243,114	53,338	Nov 19 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 18 '25	Sale	23.69	4,084	96,754	25,058	Nov 19 06:00 PM
Daly James M	Director	Nov 10 '25	Sale	22.37	30,000	670,983	4,041	Nov 12 06:00 PM
James M Daly	Director	Nov 10 '25	Proposed Sale	22.37	30,000	670,983		Nov 10 05:59 PM

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

CEO & DirectorMs. Catherine E. Owen Adams

Executive VP & CFOMr. Mark C. Schneyer

Executive VPMs. Jennifer J. Rhodes J.D.

Executive VP and Head of Research & DevelopmentDr. Elizabeth H. Z. Thompson Ph.D.

Executive VP & Chief Commercial OfficerMr. Thomas Andrew Garner

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACAD

Acadia Pharmaceuticals Inc

Upgrade your Finviz experience